Tag Archives: Drug

Drug company influence on journalism

Many times through the years, HealthNewsReview.org has criticized the National Press Foundation in Washington, DC, for accepting drug company funding for journalism training.  (See articles from June 2009, July 2009, August 2010, September 2010, October 2010, March 2014, March 2015, December 2015, November 2019. I may have missed a few, but you get the picture.) They’re doing it… Read More »

UnitedHealthcare spurns Gilead’s newer PrEP drug Descovy as Truvada generic looms: report

UnitedHealthcare has a history of limiting HIV drug costs, including offering cash incentives to patients who opt for low-priced regimens. Now, in a potentially major blow to HIV giant Gilead Sciences, the insurer has set its eyes on one of the California drugmaker’s new therapies. Gilead’s new HIV PrEP option, Descovy, will no longer be covered… Read More »

Tremfya (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis

Print this page HORSHAM, PA, July 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.[1],[2] Tremfya is the first treatment… Read More »

Brain plasticity in drug addiction: Burden and benefit

The human brain is the most complex organ in our body, and is characterized by a unique ability called neuroplasticity. Neuroplasticity refers to our brain’s ability to change and adapt in its structural and functional levels in response to experience. Neuroplasticity makes it possible for us to learn new languages, solve complex mathematical problems, acquire… Read More »